Shapiro brings more than thirteen years of drug development experience to Clinipace

Wednesday, May 20, 2009 / Morrisville, NC — Clinipace, a digital clinical research organization, today announced the addition of Mark Shapiro as Director of Clinical Solutions to its team. A trained pharmacologist, Shapiro brings more than thirteen years of drug development experience and knowledge in all phases of pre-clinical and clinical research management to his new role.

Prior to joining Clinipace, Shapiro served as Associate Practice Executive in the Clinical Development and Medical Affairs consulting practice at Campbell Alliance. As a management consultant specializing in pharmaceutical research and development process improvement, his clients included many top pharmaceutical and biotechnology companies including Amgen, Celgene, Covance, Molecular Insight Pharmaceuticals, Onyx Pharmaceuticals, Sepracor, and Upsher-Smith Labs.

Additionally, Shapiro led the operations for a drug safety research center at the Duke University School of Medicine that conducted numerous research programs including clinical, pharmacogenomic, and psychometric studies. He also managed regulatory filings and more than ten pediatric studies at several contract research organizations, including PPD and the Duke Clinical Research Institute. In addition, he has published peer-reviewed articles on clinical trial design, methods, and the impact of regulatory changes on pediatric research.

Shapiro received his MBA from Duke University and completed Masters and Doctoral work in pharmacology and biomolecular pharmacology, respectively, at the Boston University School of Medicine. He received a Bachelor’s degree in chemistry at the Virginia Polytechnic Institute and State University. In addition, he has received several professional distinctions including Duke University’s Certificate in Health Sector Management and professional certifications in both Regulatory Affairs and Clinical Research from the Regulatory Affairs Professional Society and Association of Clinical Research Professionals.

“The addition of Mark to the Clinipace team further emphasizes our commitment of bringing the best expertise to the mission of improving the clinical development process for our clients,” said Jeff Williams, Chief Executive Officer of Clinipace. “Mark brings a wealth of experience to our team and we’re pleased to leverage his knowledge as we continue to provide a technology-driven CRO model that is committed to efficiency and enhanced visibility into the performance of clinical trials.”

About Clinipace

Clinipace, an experienced digital clinical research organization (dCRO), provides on-demand software and clinical services for phase I-IV clinical trials, registries, and investigator-initiated grant management programs. We serve biopharmaceutical and medical device companies as well as academic medical centers. Optimized by TEMPO™, our web-based software platform, we deliver clinical trial and registry services at up to a 30% savings compared to traditional service providers. Learn more at